Critical Review: Tobira Development (TBRA) & BioCryst Pharmaceuticals (BCRX)
Tobira Development (NASDAQ: TBRA) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.
Earnings & Valuation
This table compares Tobira Development and BioCryst Pharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BioCryst Pharmaceuticals||$26.35 million||18.75||-$55.14 million||($0.64)||-7.84|
This is a summary of current ratings and recommmendations for Tobira Development and BioCryst Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioCryst Pharmaceuticals has a consensus target price of $8.83, suggesting a potential upside of 75.96%.
Insider and Institutional Ownership
62.4% of Tobira Development shares are held by institutional investors. Comparatively, 86.8% of BioCryst Pharmaceuticals shares are held by institutional investors. 6.2% of Tobira Development shares are held by insiders. Comparatively, 5.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This table compares Tobira Development and BioCryst Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
BioCryst Pharmaceuticals beats Tobira Development on 6 of the 9 factors compared between the two stocks.
About Tobira Development
Tobira Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company’s product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5) in late stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure. CVC is also being investigated to address primary sclerosing cholangitis (PSC), a disease which causes inflammation and scarring of the bile ducts, eventually leading to liver damage. The Company’s pipeline also includes evogliptin, a selective dipeptidyl peptidase 4 (DPP-4) inhibitor, which it plans to develop for NASH in combination with CVC.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company’s drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.
Receive News & Ratings for Tobira Development Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Development and related companies with MarketBeat.com's FREE daily email newsletter.